FDA Approves UCB's Keppra(R) for Use in Childhood Epilepsy Part 3

About UCB UCB - be a intercontinental biopharmaceutical captain beside headquarters contained using Brussels, Belgium, specialising in the field of internal uneasy arrangement disorder, allergy and respiratory illness, immune and inflammatory disorders, as well as by jewels of oncology. UCB push button products be Keppra(R) (antiepileptic), Xyzal(R) and Zyrtec(R) (antiallergics), Nootropil(R) (cerebral control regulator), Tussionex(R) (antitussive) and Metadate(R) / Equasym XL(R) (attentiondeficit/ hyperactivity disorder). UCB employ ended 8,500 individuals operating in over 40 rustic and achieve in 2004 revenues of £ 2.1 billion (including lattice sale, royalty, and fees) and an operating profit beforehand amortisation (EBITA) of £ 389 million (on a pro-forma IFRS spring plus 12 months of Celltech and excluding the Surface Specialties undertakings, divest in February 2005). UCB is scheduled in opposition Euronext Brussels with a overt market capitalization of roughly £ 5.5 billion.

For further statistics, delight note Jean-Christophe Donck Vice President, Investor Relations +32 2 5599 9264 1Glauser TA, Gauer LJ, Chen L and LEV N159 Pediatric Study Group. Multicenter, double-blind, placebocontrolled tribunal of adjunctive levetiracetam (Keppra(R)) psychiatric help (up to 60 mg/kg/day) in pediatric patients with refractory partial epilepsy. Epilepsia 2004; 45 (supplement 7): 186 2 UCB Data on File 3 Keppra(R) U.S. Package Insert 4NDCHealth Retail Pharmacy Database, May 2000 - April 2005 5IMS NDTI Drug Use, Rolling Quarter February - April 2005 6 Keppra(R) Summary of Product Characteristics